Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for ICI-Related Diarrhea
NCT04883762Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2021
- Primary completion
- May 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in diarrhea, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Incidence of fecal microbiota transplantation (FMT)-related adverse events at 7 days. Started May 2021; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT04883762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883762.